Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T10747 | CDK9-IN-9 | CDK | Cell Cycle/Checkpoint |
CDK9-IN-9 is a potent and selective CDK9 inhibitor (IC50: 1.8 nM) with anti-cancer activity. It inhibits CDK2 (IC50: 155 nM). | |||
T10746 |
CDK9-IN-8
|
CDK | Cell Cycle/Checkpoint |
CDK9-IN-8 is a highly potent and selective CDK9 inhibitor (IC50: 12 nM). | |||
T10742 |
CDK9-IN-10
|
CDK | Cell Cycle/Checkpoint |
CDK9-IN-10 是一种有效的 CDK9 抑制剂。CDK9-IN-10 是 PROTAC CDK9 degrader-2 的配体。 | |||
T10745 |
CDK9-IN-7
|
CDK | Cell Cycle/Checkpoint |
CDK9-IN-7 (compound 21e) 是一种高效选择性的,具有口服活性的 CDK9/cyclin T 抑制剂 (IC50=11 nM),与抑制其他 CDK 相比更有效 (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM)。CDK9-IN-7 具有抗癌活性并没有明显的毒性。CDK9-IN-7 诱导非小细胞肺癌 (NSCLC) 细胞凋亡,在 G2 期阻滞细胞周期,并具有抑制非小细胞肺癌干细胞特性。 | |||
T14918 |
CDK9-IN-2
N2'-(反式-4-氨基环己基)-5'-氯-N6-[(3-氟苯基)甲基]-[2,4'-联吡啶]-2',6-二胺 |
Others; CDK | Cell Cycle/Checkpoint; Others |
CDK9-IN-2 是一种特异性CDK9抑制剂。它在 A2058 皮肤细胞系(72 小时)和 H929 多发性骨髓瘤细胞系(72小时)的IC50分别为 7 nM 和 5 nM。 | |||
T39354 |
CDK9-IN-12
CDK9-IN-12 |
||
CDK9-IN-12 displays the optimal CDK9 inhibitory activity with an IC 50 value of 5.41 nM. | |||
T10743 |
CDK9-IN-11
|
CDK | Cell Cycle/Checkpoint |
CDK9-IN-11 是一种有效的CDK9抑制剂,可作为 PROTAC CDK9 Degrader-1 的配体。 | |||
T10741 | CDK9-IN-1 | CDK | Cell Cycle/Checkpoint |
CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection (IC50: 39 nM for CDK9/CycT1). | |||
T79631 |
CDK9-IN-26
|
CDK | Cell Cycle/Checkpoint |
CDK9-IN-26 (化合物1d) 为CDK9抑制剂,具有0.18 µM的IC50值。 | |||
T40353 |
CDK7/9-IN-1
CDK7/9-IN-1 |
||
CDK7/9-IN-1 is a specific inhibitor of cyclin-dependent kinases 7/9 (CDK7/9). It specifically targets CDK7, while also displaying inhibitory activity against CDK9. CDK7/9-IN-1 demonstrates excellent inhibitory potency against CDK7, with IC50 values of 0.0656 μM and 0.00574 μM without pre-incubation and after 3 hours pre-incubation, respectively. Furthermore, CDK7/9-IN-1 inhibits CDK9 with an IC50 of 2.14 μM after 3 hours pre-incubation. Its application in cancer research makes it valuable for su... | |||
T36743 |
CDK7/9 tide
|
||
CDK7/9 tide is peptide substrate for CDK7 or CDK9[1]. [1]. Robert T, et, al. Development of a CDK10/CycM in vitro Kinase Screening Assay and Identification of First Small-Molecule Inhibitors. Front Chem. 2020 Feb 27; 8:147. | |||
T40047 |
CDK6/9-IN-1
CDK6/9-IN-1 |
||
CDK6/9-IN-1 (compound 66) is a potent dual inhibitor of CDK 6 and CDK 9 that can be administered orally. It exhibits inhibitory activity with IC 50 values of 40.5 nM and 39.5 nM against CDK6 and CDK9, respectively. | |||
T70897 | Zotiraciclib HCl | ||
Zotiraciclib, also known as TG02 and SB1317, is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. Zotiraciclib may be useful for the treatment of cancer that crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9). It is one of a number of CDK inhibitors under investigation; others targeting CDK9 for the treatment of acute myeloid leukemia include alvocidib and atuveciclib. Myc overexpression is a known factor in many cancers, w... | |||
T70988 |
Ibulocydine
|
||
Ibulocydine is a potent CDK inhibitor. Ibulocydine has high activity against Cdk7/cyclin H/Mat1 and Cdk9/cyclin T. Ibulocydine inhibited the growth of HCC cells more effectively than other Cdk inhibitors, including olomoucine and roscovitine, whereas ibulocydine as well as the other Cdk inhibitors and BMK-Y101 minimally influenced the growth of normal hepatocyte cells. Ibulocydine induced apoptosis in HCC cells, most likely by inhibiting Cdk7 and Cdk9. In vitro treatment of HCC cells with ibuloc... |